Marketed by Actelion in the US only
Ventavis® (iloprost) is an inhaled synthetic analog of prostacyclin (PGI2) that produces potent pulmonary vasodilation and inhibits platelet aggregation, among other benefits. Prostacyclin functions as a hormone, binding to receptors on smooth muscle cells, thereby affecting their function. Prostacyclin has multiple physiological effects, including vasodilation, inhibition of platelet aggregation, antiproliferation, anti-inflammation, and enhanced cardiac contractility. Ventavis® is an inhaled synthetic prostacyclin which has been shown to:
- Significantly increase (p = 0.0033) patient improvement after 12 weeks of treatment compared to baseline on a composite endpoint of improved exercise capacity 30 minutes after dosing, improvement of at least one NHYA class and no clinical deterioration.
- Significantly improve 6-minute walk distance at week 12 with a 10% or greater increase in individual walk distance (p < 0.01).
- Significantly improve patients' functional class at week 12 (p = 0.03).
For patients with PAH (WHO Group 1) with NHYA Class III or IV symptoms
